The PROSE trial, the first prospective, randomized proteomic stratified phase III study, was designed to evaluate the predictive value of the VeriStrat test on the outcome in advanced NSCLC patients treated with either EGFR-TKIs or standard chemotherapy [73]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.